Please login to the form below

Not currently logged in
Email:
Password:

Medtronic wins In House Team of the Year at Communiqué Awards

PR team for Europe, Middle East and Canada recognised at health comms event

Communique 2013 winner in-house team

Medtronic's communications team for Europe, Middle East and Canada last week picked up the In House Team of the Year prize at the Communiqué Awards.

The event, which recognises excellence and best practice in local, European and international healthcare communications, saw the Medtronic team impress the judges with their “passion, enthusiasm and belief”.

Medtronic faced stiff competition in the category, particularly from GlaxoSmithKline Consumer Healthcare and Merck Sharp & Dohme UK, both of whom were highly commended.

But Medtronic won out, thanks in part to a series of highlights from their work that included the team's ability to turn 25 news opportunities into 11,000 articles, 45 TV appearances and present five billion opportunities to read.

“We were impressed by their careful consideration of career progression and learning opportunities,” said one judge.

“What became obvious to us, as judges, was that in order for their model to work, they really need to trust each other and we could see that they genuinely had each others' backs.”

The Communiqué Awards are run by PMLiVE publishers PMGroup and the awards ceremony took place at London's Grosvenor House Hotel, Park Lane, on July 4.

• See the full results of the Communiqué Awards 2013
• See all the photos from the Communiqué Awards 2013

8th July 2013

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
11 London

The biggest problems facing humanity today are health-related, and the health of people, animals and our planet are inextricably linked. ...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...